argenx SE
NASDAQ:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
NASDAQ:ARGX
Watchlist
Price: 647.94 USD 0.21%
Market Cap: 38.7B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ARGX stock under the Base Case scenario is 863.87 USD. Compared to the current market price of 647.94 USD, argenx SE is Undervalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ARGX Relative Value
Base Case
863.87 USD
Undervaluation 25%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

13
P/S
P/S
Price to Sales
13
vs History
15
vs Industry
34
Median 3Y
0
Median 5Y
0
Industry
7.5
Forward
10.7
More Details
30.9
P/E
P/E
Price to Earnings
30.9
vs History
11
vs Industry
4
Median 3Y
0
Median 5Y
0
Industry
24.2
Forward
55.5
More Details
98.5
P/OCF
P/OCF
Price to OCF
98.5
vs History
1
vs Industry
Median 3Y
0
Median 5Y
0
Industry
20.5
More Details
131.7
P/FCFE
P/FCFE
Price to FCFE
131.7
vs History
1
vs Industry
Median 3Y
0
Median 5Y
0
Industry
22.4
More Details
6.5
P/B
P/B
Price to Book Value
6.5
vs History
36
vs Industry
11
Median 3Y
6.9
Median 5Y
5.4
Industry
2.9
More Details
11.8
EV/S
EV/S
Enterprise Value to Sales
11.8
vs History
15
vs Industry
30
Median 3Y
0
Median 5Y
0
Industry
8
Forward
9.7
More Details
13.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
13.2
vs History
15
vs Industry
29
Median 3Y
0
Median 5Y
0
Industry
10.2
More Details
73.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
73.7
vs History
15
vs Industry
0
Median 3Y
0
Median 5Y
0
Industry
5.1
Forward
44.6
More Details
77.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
77.2
vs History
6
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
Forward
46.9
More Details
89.2
EV/OCF
EV/OCF
Enterprise Value to OCF
89.2
vs History
1
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.8
More Details
116.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
116.7
vs History
1
vs Industry
Median 3Y
0
Median 5Y
0
Industry
4
More Details
13.2
EV/IC
EV/IC
Enterprise Value to IC
13.2
vs History
17
vs Industry
10
Median 3Y
8.5
Median 5Y
5.1
Industry
5.1
More Details

Multiples Across Competitors

ARGX Competitors Multiples
argenx SE Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
argenx SE
NASDAQ:ARGX
34.1B USD 13 30.9 73.7 77.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 980 524.7 -161 504.4 -196 117.9 -193 879.9
US
Abbvie Inc
NYSE:ABBV
359.6B USD 6.2 96.6 15.9 23.1
US
Amgen Inc
NASDAQ:AMGN
156B USD 4.5 23.6 18.5 18.5
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD 5.2 23.6 11 15.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 073.2 -529 -576.1 -560.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.1B USD 8.9 27.8 20.5 21.4
AU
CSL Ltd
ASX:CSL
130.8B AUD 5.6 31.2 19 23.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.6B USD 4.3 13.6 12.2 13.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
57.2B USD 23.2 -179.1 -447.3 -307
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.2 -66 -59.6
P/S Multiple
Revenue Growth P/S to Growth
NL
argenx SE
NASDAQ:ARGX
Average P/S: 3 089 335.3
13
40%
0.3
FR
Pharnext SCA
OTC:PNEXF
33 980 524.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.2
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
E
Epizyme Inc
F:EPE
2 073.2
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.9
10%
0.9
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
4%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
23.2
31%
0.7
US
S
Seagen Inc
F:SGT
20
30%
0.7
P/E Multiple
Earnings Growth PEG
NL
argenx SE
NASDAQ:ARGX
Average P/E: 35.3
30.9
28%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 504.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
96.6
88%
1.1
US
Amgen Inc
NASDAQ:AMGN
23.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
189%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
N/A N/A
AU
CSL Ltd
ASX:CSL
31.2
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
7%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -179.1 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
argenx SE
NASDAQ:ARGX
Average EV/EBITDA: 24.4
73.7
727%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 117.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.5
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
11
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.5
17%
1.2
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -447.3 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
argenx SE
NASDAQ:ARGX
Average EV/EBIT: 27.6
77.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 879.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.5
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
15.1
12%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.4
17%
1.3
AU
CSL Ltd
ASX:CSL
23.8
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.8
10%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -307 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A

See Also

Summary
ARGX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ARGX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ARGX stock valuation using valuation multiples.
Wall Street Estimates
ARGX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ARGX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 275,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.